Should Eli Lilly Investors Worry About This Unexpected FDA Move?
Lilly has invested billions of dollars to ramp up production capacity.
Eli Lilly to trial use of weight loss drugs to combat unemployment in UK
The U.K. is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with weight-loss treatment giant, Eli Lilly. The U.S. pharmaceutical company and ...
Lilly reports one-year histologic outcomes in Phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease
Data show more patients treated with mirikizumab achieved histologic response at Week 52 compared to ustekinumab New data are first-of-its-kind analysis of microscopic mucosal resolution that go be...
3 No-Brainer Growth Stocks to Buy in October
These stocks look like slam-dunk picks for growth investors.
Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
In a year and a half, Eli Lilly NYSE: LLY has roughly doubled in value. It is now the most valuable pharmaceutical company in the world.
2 No-Brainer Dividend Growth Stocks to Buy Right Now
These two pharmaceutical giants are positioned for growth with their innovative diabetes and obesity treatments.
Why Eli Lilly Was Such a Healthy Stock Today
The pharmaceutical giant's weight loss medication Zepbound was in the spotlight again Tuesday.
LLY: Legal Battle Over FDA's Decision on Eli Lilly's Weight Loss Drug
The Outsourcing Facilities Association, representing companies producing generic versions of Eli Lilly's (LLY, Financial) weight loss drug, has filed a lawsuit against the U.S. Food and Drug Admini...
Billion-Dollar News for Eli Lilly Stock Investors
Eli Lilly shares have soared thanks to excitement about the company's position in the weight loss drug market.
Compounding group sues FDA for removing Lilly's weight loss drug from shortage list
A drug compounding industry group on Monday sued the U.S. Food and Drug Administration over its decision to take Eli Lilly's blockbuster weight loss and diabetes drugs from its shortage list last w...
Eli Lilly (LLY) Rises But Trails Market: What Investors Should Know
Eli Lilly (LLY) concluded the recent trading session at $887.16, signifying a +0.18% move from its prior day's close.
Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
Thursday, The FDA determined the shortage of Eli Lilly And Co's LLY tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved.
The Big 3: LLY, CVX, RBLX
Today's Big 3 dives into medical, energy and digital entertainment names. @ProsperTradingAcademy's Mike Shorr joins Rick Ducat and Nicole Petallides to break down the technical trends in Eli Lilly ...
Eli Lilly's weight-loss and diabetes drugs are no longer in shortage, says FDA
The U.S. Food and Drug Administration said Eli Lilly's diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage signaling that the company has succeeded in expandi...
Eli Lilly's Weight Loss Drugs No Longer In Shortage. It's Bad News for These Stocks.
Blockbuster drugs Zepbound and Mounjaro have come off the FDA's shortage list.
Related Companies